Znanstveniki FDA nasprotujejo prizadevanjem Trumpove administracije za lažji dostop do peptidov.
Predlagana politika, ki je bila namenjena olajšanju dostopa Američanov do nepreverjenih peptidnih zdravil, ki jo je zagovarjal zdravstveni minister Robert F. Kennedy Jr., se je soočila z znatnim nasprotovanjem večine znanstvenega osebja uprave za hrano in zdravila. Po besedah šestih posameznikov, ki so seznanjeni s postopkom, so ti strokovnjaki imeli omejen prispevek v fazi priprave in opozorili, da bi ukrep lahko ogrozil osnovni mandat FDA, da prepreči vstop nepreverjenih zdravstvenih izdelkov na trg. Politika se posebej nanaša na injekcijske peptide, kot sta BPC-157 in TB-500, ki so trenutno razvrščeni kot nezakonita zdravila zaradi pomanjkanja strogih testov varnosti in učinkovitosti, vendar so priljubljeni v wellness sektorju zaradi domnevnih koristi pri okrevanju po poškodbah in izgradnji mišic. Čeprav so bili prvotni načrti namenjeni uradni opredelitvi teh snovi kot varnih za farmacevtske združenja, so pomisleki FDA privedli do revidiranega pristopa, ki je agenciji ukazal, naj preprosto ne uveljavlja predpisov proti specializiranim farmacevtom, ki jih prodajajo. Kennedy, ki je javno pohvalil peptide in navedel osebno uporabo BPC-157 za poškodbo mišic, trdi, da omejevanje dostopa prisili potrošnike k nevarnim alternativam na sivem trgu.
The U.S. Department of Health and Human Services announced on October 28 that it will exercise enforcement discretion to prevent federal action against state-licensed pharmacies, federal facilities, and licensed physicians who compound six specific peptide bulk drug substances. The policy, published in the Federal Register, effectively permits the production and sale of BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500 without prior approval from the Food and Drug Administration. HHS stated the measure serves as a controlled alternative to purchasing these compounds from potentially unsafe foreign sources, aiming to reduce reliance on gray and black markets. The department noted that while compounded drugs are not FDA-approved and thus lack pre-market review for safety, effectiveness, or quality, they can address specific medical needs for certain patients. The initiative follows a July meeting of the FDA’s Pharmacy Compounding Advisory Committee, which debated whether to add these substances to the Section 503A Bulks List. That list determines which materials licensed entities can use to create drug products that are not components of existing FDA-approved drugs and lack applicable United States Pharmacopeia or National Formulary monographs. The advisory panel voted to recommend placing six of the seven peptides under consideration onto the list, excluding Emideltide. Although the committee’s vote is non-binding and rests with FDA authorities to implement, no formal FDA decision had been released prior to the HHS announcement. Consequently, HHS Secretary Robert F. Kennedy Jr. utilized his authority to halt enforcement actions against practitioners using these substances, thereby implementing the committee’s recommendation indirectly. Internal dynamics at the FDA played a significant role in the policy’s evolution. According to six individuals familiar with the development process, the majority of FDA scientific staff opposed the initial plan, warning that it could undermine the agency’s mission to keep unproven products off the U.S. market. These staff members indicated they had limited input during the drafting phase. Initially, HHS officials sought an official FDA regulation adding the peptides to the safe-for-compounding list. However, FDA officials cautioned that scientific staff held substantial safety concerns and would not support such a regulation. In response, HHS shifted strategy to an enforcement discretion policy. Despite their opposition, FDA staffers provided technical assistance in drafting the final plan, contributing guardrails such as requirements for pharmacies to source peptide ingredients from FDA-regulated factories. The policy mandates strict compliance for participating entities. Pharmacies must hold state licenses and adhere to federal laws governing compounding. Specifically, active ingredients must be accompanied by valid certificates of analysis, and products must be prepared based on valid, patient-specific prescriptions. Additional rules govern the packaging and labeling of these peptides. HHS asserted that this limited approach discourages the widespread use of research-use-only peptides from foreign manufacturers, which it determined pose safety risks to U.S. patients. A separate document on the HHS website stated that the Secretary determined the policy advances patient choice and freedom while protecting patient safety. Reactions to the decision have been sharply divided. Proponents view the move as a victory for health freedom and a necessary step to eliminate unsafe import channels. Lee Rosebush, chair of the American Academy of Peptide Medicine, described the policy as a vital step toward restoring safe, physician-supervised access. Commercial interests also responded positively; analysts estimate the peptide market could reach $3.3 billion. Shares of Hims & Hers rose 5 percent following the announcement, as the company had reportedly planned to offer peptides in 2026. Conversely, public health experts and consumer advocates raised alarms regarding the lack of scientific evidence supporting these substances. Critics emphasized that the peptides have not undergone the rigorous testing required for standard drug approvals. Fred Mills, chief policy officer for Americans for Safe and Effective Medicines, stated that American consumers should not be treated like guinea pigs and argued that the current approach fails to balance safety with access. During the July hearings, Dr. Adriane Fugh-Berman, a professor of pharmacology and physiology at Georgetown University Medical Center, told the committee that the peptides are untested and poorly characterized experimental drugs. She cited incidents where two women required emergency treatment after receiving peptides at a Las Vegas festival. Consumer groups, including the Center for Science in the Public Interest, labeled the bypass of the standard evidence-based approval process as unprecedented and dangerous. Background on the substances reveals that peptides are short chains of amino acids, some of which occur naturally in the body to trigger hormones related to growth, metabolism, and healing. While pharmaceutical companies have marketed similar compounds for conditions like diabetes and weight loss, the six substances covered by this policy have not passed the FDA’s rigorous vetting process. BPC-157 and TB-500, included in the list, are promoted for injury recovery and muscle building and are classified as doping substances by international sports authorities. Kennedy, who has identified himself as a big fan of peptides, recently described using BPC-157 to treat a personal muscle injury. He has frequently cited the prevalence of Americans importing these products from China and other countries via online marketplaces as justification for the new domestic access pathway. Historically, decisions regarding compounding pharmacies have originated from the FDA, particularly since a 2012 outbreak of fungal meningism linked to contaminated injections from a Massachusetts compounding pharmacy heightened scrutiny of the industry. Compounding has evolved from a niche service into a multibillion-dollar sector. Former FDA officials noted that it is extremely rare for HHS to lead policy drafting in this area, although federal law grants HHS overarching authority over drug regulations, which are typically delegated to the FDA. The new policy stands as a distinct departure from previous administrative practices, prioritizing immediate availability over completed regulatory reviews.
Pojdite k primarnim virom (5)
Uradni viri, na katerih temelji poročanje. Preberite jih neposredno in se izognite uokvirjanju.
Predlagana politika, ki je bila namenjena olajšanju dostopa Američanov do nepreverjenih peptidnih zdravil, ki jo je zagovarjal zdravstveni minister Robert F. Kennedy Jr., se je soočila z znatnim nasprotovanjem večine znanstvenega osebja uprave za hrano in zdravila. Po besedah šestih posameznikov, ki so seznanjeni s postopkom, so ti strokovnjaki imeli omejen prispevek v fazi priprave in opozorili, da bi ukrep lahko ogrozil osnovni mandat FDA, da prepreči vstop nepreverjenih zdravstvenih izdelkov na trg. Politika se posebej nanaša na injekcijske peptide, kot sta BPC-157 in TB-500, ki so trenutno razvrščeni kot nezakonita zdravila zaradi pomanjkanja strogih testov varnosti in učinkovitosti, vendar so priljubljeni v wellness sektorju zaradi domnevnih koristi pri okrevanju po poškodbah in izgradnji mišic. Čeprav so bili prvotni načrti namenjeni uradni opredelitvi teh snovi kot varnih za farmacevtske združenja, so pomisleki FDA privedli do revidiranega pristopa, ki je agenciji ukazal, naj preprosto ne uveljavlja predpisov proti specializiranim farmacevtom, ki jih prodajajo. Kennedy, ki je javno pohvalil peptide in navedel osebno uporabo BPC-157 za poškodbo mišic, trdi, da omejevanje dostopa prisili potrošnike k nevarnim alternativam na sivem trgu.
Ocena pristranskosti (Progresivno): V članku je politika označena kot sporna izvršna prehitrost, ki spodkopava uveljavljene znanstvene zaščitne ukrepe. S poudarkom "prevelikega odpora" strokovnjakov FDA in opisom ciljanih snovi kot "nedokazanih" in "nezakonitih" se pripoved ujema s pogledom, ki kritizira
Zakaj dejstva (85): Strong factual grounding based on anonymous sources describing internal processes (White House review, FDA staff opposition). Accurately describes the policy's function (directing FDA not to act) and the status of the peptides (unproven/unapproved). The details about the 'doping substances' classifi
Zakaj objektivnost (65): Relatively objective compared to others. Presents the conflict between HHS/Kennedy and FDA staff neutrally. Uses standard journalistic attribution ('according to six people familiar'). Avoids emotionally charged adjectives for the peptides themselves, focusing instead on the procedural dispute and t
Ameriško ministrstvo za zdravje in socialne storitve (HHS) je izdalo politiko diskrecijskega izvrševanja, ki dovoljuje državnim lekarnam in zdravnikom, da sestavljajo in prodajajo šest specifičnih peptidov, ne da bi se soočili s pravnimi ukrepi zvezne vlade, kljub pomanjkanju uradnega odobritve FDA. Ta upravni ukrep sledi nezavezujočemu priporočilu Svetovalnega odbora za farmacevtske spojine FDA, da se te snovi dodajo na seznam izdelkov v razdelku 503A, proces, ki običajno zahteva končno odobritev FDA, ki pa se še ni zgodil. HHS je navedel, da je cilj politike ustvariti nadzorovano domačo alternativo potrošnikom, ki kupujejo neregulirane peptide od tujih prodajalcev ali spletnih tržnic. Medtem ko je oddelek priznal, da združena zdravila obidejo standardne preglede varnosti in učinkovitosti pred dajanjem na trg, je poudaril veliko povpraševanje po teh združenjih med bolniki. Politika vključuje BPC-157, Epitalon, KPV, MOTS-c, Semax in TB-500, vendar izključuje Emideltid, ki ga je svetovalni odbor zavrnil.
Ocena pristranskosti (Konservativno): V članku je regulativni preobrat označen kot pozitiven razvoj, izrecno pa je označen kot "velika zmaga" za "zdravstveno svobodo" in zagovornike zdravljenja. Pripiše politiko ministrstvu za zdravje in zdravje Robert F. Kennedyju Jr. in predlaga, da poteza odraža njegovo osebno frustracijo zaradi počasnega delovanja FDA.
Zakaj dejstva (85): Accurately identifies the six specific peptides, the nature of the 'enforcement discretion' policy, and the prior PCAC vote. It correctly notes the policy allows compounding without FDA approval. However, it frames the move as a 'major win' and suggests RFK Jr.'s 'frustration,' which are interpretiv
Zakaj objektivnost (40): Highly biased. Uses loaded terms like 'sketchy foreign pharmacies,' 'health freedom,' and 'major win.' Explicitly takes a pro-policy stance ('win for peptide proponents') and speculates on the Secretary's personal feelings, lacking neutrality.
Ameriško ministrstvo za zdravje in socialne storitve je napovedalo politiko, ki licenciranim farmacevtom omogoča izvzetje iz kazenskega pregona zaradi dajanja določenih neodobrenih peptidov, vključno z BPC-157 in Semaxom. Ta odločitev razveljavlja prejšnje omejitve FDA, uvedene leta 2023 zaradi varnostnih pomislekov, in sledi julijskemu sestanku svetovalnega odbora, na katerem so člani s povezavami v industriji priporočili, da se praksa dovoli zaradi ugovorov osebja. Sekretar HHS Robert F. Kennedy Jr., ki je javno podprl te snovi, je podpisal politiko, ki navaja izboljšano dostopnost bolnikov in odpravo nevarnih črnih trgov. Sporočilo je pozitivno vplivalo na finančne trge, zaradi česar so delnice ponudnika telemedicinskih storitev Hims & Hers znatno porasle, saj analitiki predvidevajo več milijardno tržno priložnost. Medtem ko zagovorniki trdijo, da ta poteza prinaša varen dostop pod nadzorom zdravnika, zagovorniki javnega zdravja opozarjajo, da dajanje teh spojin brez znanstvenih dokazov predstavlja tveganje za varnost potrošnikov.
Ocena pristranskosti (Konservativno): V članku je regulativni premik predstavljen predvsem skozi lečo "izbira bolnika" in "svoboda", izrazi, ki so pogosto povezani z libertarijanskimi ali desničarskimi političnimi argumenti v zvezi z telesno avtonomijo in deregulacijo. Poudarja vlogo sekretarja Robert F. Kennedy Jr.,
Zakaj dejstva (80): Mostly accurate regarding the policy details, the list of peptides, and the date. It incorrectly states the policy was published on Oct. 28 when the primary source specifies Oct. 30 (though it later mentions the Oct. 30 date in the quote). It accurately quotes the HHS rationale. The claim that the F
Zakaj objektivnost (50): Somewhat slanted. Describes the peptides as 'largely scientifically unproven' and highlights the conflicts of interest of the committee members ('consulted with or were employed by companies...'). While these points may be true, the selection of facts emphasizes the negative aspects of the process a
STAT NewsNeodvisenProgresivnoDejstva 75Objektivnost 55
Ameriško ministrstvo za zdravje in socialne storitve je izdalo politiko, ki dovoljuje farmacevtskim združenjem, da pod diskrecijsko pristojnostjo izvajanja zakonodaje izdelujejo določene peptidne izdelke. Ta poteza poveča dostop do eksperimentalnih zdravilnih terapij, povezanih z gibanjem Make America Healthy Again. Politika posebej zajema šest peptidov, ki jih je svetovalni odbor FDA predhodno priporočil za odobritev v juliju. Odločitev je bila sprejeta, medtem ko FDA še naprej preučuje širše predpise glede proizvodnje peptidov. V članku je omenjeno, da Robert F. Kennedy mlajši podpira te terapije kljub omejenim dokazom o njihovi varnosti ali učinkovitosti.
Ocena pristranskosti (Progresivno): V članku je politika postavljena skozi lečo gibanja "Naj bo Amerika spet zdrava", ki se pogosto uporablja v kritičnih kontekstih v glavnih medijih. Izrecno poudarja pomanjkanje znanstvenih dokazov o varnosti in učinkovitosti terapij ter to primerja z
Zakaj dejstva (75): Accurate summary of the policy's effect (temporary allowance via enforcement discretion) and the connection to the July FDA advisory panel. Mentions the MAHA movement, which provides context but is not in the primary source. The core legal mechanism described matches the source document.
Zakaj objektivnost (55): Mildly biased. Uses phrases like 'experimental wellness therapies' and links the policy to the 'Make America Healthy Again movement,' which frames the issue politically. The tone is more descriptive than the first article but still carries an implicit skepticism by labeling the therapies 'experiment
STAT NewsNeodvisenProgresivnoDejstva: uradni vir/dokument ni zaznanObjektivnost 60
Ameriško ministrstvo za zdravje in socialne storitve je izdalo novo politiko, ki dovoljuje licenciranim lekarnam in zdravnikom, da sestavijo šest eksperimentalnih peptidov, vključno z BPC-157 in TB-500, ne da bi se soočili s sodnimi ukrepi. Ta regulativni preobrat je namenjen podpori rastočemu trgu za te spojine, ki se pogosto tržijo za zdravljenje poškodb in druge koristi za zdravje. Vendar pa je odločitev privedla do kritik kariernega znanstvenika pri Agenciji za hrano in zdravila, ki trdi, da ni dovolj znanstvenih dokazov, da bi potrdili varnost ali učinkovitost teh snovi. Ta ukrep predstavlja pomembno odstopanje od standardnih regulativnih praks in poudarja napetosti med cilji upravne politike in znanstvenim soglasjem znotraj zveznih zdravstvenih agencij.
Ocena pristranskosti (Progresivno): V članku je politika HHS označena kot "regulativni zagon", ki ga je spodbudila "Trumpova administracija" in je ta ukrep izrecno povezala s specifičnim političnim subjektom. V poročilu je poudarjen konflikt z "raziskovanimi znanstveniki FDA" in opaženo njihovo nasprotovanje, ki temelji na "manjše količine dokazov", pri čemer je znanstveno telo pozicioniralo
Zakaj dejstva: uradni vir/dokument ni zaznan
Zakaj objektivnost (60): Moderate bias. The headline uses emotive language ('green lights', 'floodgates'). The subhead calls the peptides 'experimental' and notes 'scant evidence,' which reflects a skeptical stance but is grounded in the reported conflict between HHS and FDA staff. Less overtly partisan than Article 0 but s
Kako je poročala vsaka stran
Isti dogodek, razvrščen po političnem nagibu medijev, ki so o njem poročali.
progresivno
sredina
konservativno
★
Kako je poročala vsaka stran
Podprite neodvisne novice z zavedanjem pristranskosti in odklenite družbeni utrip, glasovanje skupnosti in vse druge funkcije za podpornike.
United States
